Heron Therapeutics (HRTX) Stock Advancing on Positive Analyst Note

Shares of Heron Therapeutics (HRTX) are rising, up 4.77% to $30.87 after JMP Securities increased its price target to $33 from $25 while maintaining its "outperform" rating.

"We increase our price target based on a risk-adjusted, discounted cash flow analysis driven by a higher valuation for the pain program HTX-011," JMP Securities analysts said.

The upcoming, placebo-controlled Phase 2 bunionectomy study will show improved pain control with HTX-011 over two to three days, compared to PCRX's Exparel Phase 3 data, according to the analyst note.

 The company believes that 5% penetration into eligible surgical procedures is reasonable, and assuming 40 million procedures at today's Exparel price implies $500 million in U.S. sales, JMP Securities added.

Heron Therapeutics is a biotechnology company that uses its technology to develop products to address unmet medical needs and to improve the therapeutic profile of injectable pharmaceuticals.

For more on Heron, click here

HRTX Chart HRTX data by YCharts

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists